ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Microbiome research supports
use of Steriwave
Ondine Biomedical demonstrated that
photodisinfection does not harm the nasal microbiome
Research presented by Canadian life sciences company,
Ondine Biomedical Inc. (LON:OBI), at the prestigious
SPIE
Photonics West conference in San Francisco,
California shows that treatment with its Steriwave® Nasal
Photodisinfection System significantly reduces pathogens in the
nose - a reservoir for bacteria - yet does not produce long-term
adverse effects on the nasal microbiome.[*]
Upon analysis of nasal swab samples, the research
demonstrated an immediate and highly significant (99.9+% ~3
log10) reduction in viable bacterial cells and number of
species, sustained for at least 24 hours. Importantly, within a
week, the microbiome rebounded to its original diversity and
quantity. These findings support Steriwave as an efficient,
potent, short-acting, and non-selective method of nasal
decolonization, with the advantage of rapid recovery of the native
microbiome post-treatment.
In comparison to antibiotics, the study
demonstrated that Steriwave is far less likely to significantly
alter the native microbiota. The antibiotic mupirocin, commonly
used for nasal decolonization, has been shown to affect microbiota
diversity for over 6 months, allowing disease-causing pathogens
like Staphylococcus aureus
to colonize the nose before beneficial species, putting patients at
increased risk of infection.[1] Steriwave,
in contrast, offers a more favourable profile with the study
results showing a reduced risk of long-term microbiome disruption,
as the microbiome consistently returns to baseline.
Notably, minimizing microbiome disruption is
also important in safeguarding immune function, reducing
vulnerability to infectious diseases by maintenance of a
microecological environment populated by beneficial commensal
microbes instead of disease-causing species.[2] The oral research presentation, delivered by
Ondine's Director of Research and Development, Dr. Caetano Sabino,
reported results from an exploratory study involving 35 healthy
volunteers, examining the responses of the nasal microbial
population after Steriwave treatment.
Organized by SPIE, the international society for
optics and photonics, SPIE Photonics West is the largest annual
event for optic and photonic technologies and one of the world's
largest scientific conferences. Ondine's oral presentation, titled
"Microbiome Analysis of Photodynamic Nasal Decolonization," was
delivered at 10:20am on Tuesday 30 January, as part of the
"Photonic Diagnosis, Monitoring, Prevention, and Treatment of
Infections and Inflammatory Diseases" session.
**ENDS**
Ondine Biomedical
Inc.
|
|
Carolyn Cross, CEO
|
+001 (604) 665 0555
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Asha Chotai, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About SPIE Photonics
West
SPIE Photonics West is the optics and photonics
industry's preeminent annual conference and exhibition and is one
of the largest scientific conferences in the world. Its scope
covers all areas regarding the use of light for scientific and
technological applications. The conference brings together tens of
thousands of researchers, innovators, engineers, and business
leaders from across the globe for an engaging week of research
sharing, collaboration forming, and innovation-inspiring exchanges.
The week will include more than 4,500 technical presentations as
well as showcasing over 1,200 companies in three focused
exhibitions.
About Ondine
Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life science
company innovating in the field of photodisinfection therapies.
Ondine has a pipeline of investigational products, based on its
proprietary photodisinfection platform, in various stages of
development. Ondine's nasal photodisinfection system has a CE
mark in Europe and the UK and is approved in Canada and several
other countries under the name Steriwave®. In the US, it has
been granted Qualified Infectious Disease Product designation and
Fast Track status by the FDA and is currently undergoing clinical
trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns, and other indications.
About Nasal
Photodisinfection
Ondine's Steriwave® Nasal
Photodisinfection System is a patented technology using a
proprietary light-activated antimicrobial (photosensitizer) to
destroy pathogens. The photodisinfection treatment is carried out
by a trained healthcare professional and is an easy to use,
painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the
area with a specific wavelength of red laser light for less than
five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens. A key
benefit of this approach, unlike with antibiotics, is that
pathogens do not develop resistance to the therapy.
Nasal decolonization with antibiotics is
already standard practice in many hospitals prior to surgery, as
pathogens in a patient's nasal cavities are a major cause of
surgical site infections (SSIs). Nasal decolonization is
recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections,[3]
and the Society for Healthcare Epidemiology of America (SHEA)
guidelines, published in May 2023, recommend nasal decolonization
for major surgical procedures.[4]
However, there is a growing need to reduce antibiotic
use and find non-antibiotic methods of nasal decolonization as
resistance rates have been reported as high as 81%.[5]
[1] Baede VO, Barray A,
Tavakol M, Lina G, Vos MC, Rasigade JP. Nasal
microbiome disruption and recovery after mupirocin treatment in
Staphylococcus aureus carriers and noncarriers. Sci Rep. 2022 Nov
17;12(1):19738. doi: 10.1038/s41598-022-21453-4. PMID: 36396730;
PMCID: PMC9671894.
[2] Cho I, Blaser MJ.
The human microbiome: At the interface of health and disease. Nat
Rev Genet. 2012; 13: 260.
Arrieta M-C, Stiemsma LT, Amenyogbe N, Brown
EM, Finlay B. The intestinal microbiome in early life: Health and
disease. Front Immunol. 2014; 5: 427.
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E.
Current understanding of dysbiosis in disease in human and animal
models. Inflamm Bowel Dis. 2016; 22:
1137-1150.
[3]
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2
[4] Calderwood MS,
Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical
site infections in acute-care hospitals: 2022 Update. Infect
Control Hosp Epidemiol. 2023;44(5):695-720.
doi:10.1017/ice.2023.67
[5] Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance:
clinical implications and potential alternatives for the
eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692.
doi:10.1093/jac/dkv169